J&J Tops 3Q Estimates, Boosts Full-Year Profit Guidance

The transcript discusses Johnson & Johnson's strong quarterly performance across its consumer, pharmaceutical, and medical device segments. It highlights the relaunch of the baby franchise, the development of new medicines like Esketamine, and the company's strategic approach to acquisitions. The conversation also touches on transparency in pharmaceutical pricing and the importance of innovation to stay competitive.

What strategies has Johnson and Johnson implemented to respond to the needs of millennial parents?

How does Johnson and Johnson plan to expand its pharmaceutical portfolio?

What is the significance of Esketamine in the treatment of major depressive disorder?

What are the potential impacts of the Trump administration's new requirement for pharmaceutical pricing transparency?

What challenges does Johnson and Johnson face in maintaining innovation across its segments?